CPIX CUMBERLAND PHARMACEUTICALS INC

Nasdaq cumberlandpharma.com


$ 3.37 $ 0.08 (2.25 %)    

Tuesday, 21-Oct-2025 17:35:37 EDT
QQQ $ 610.88 $ 0.00 (0 %)
DIA $ 469.05 $ 0.00 (0 %)
SPY $ 671.57 $ 0.00 (0 %)
TLT $ 92.00 $ 0.00 (0 %)
GLD $ 377.98 $ 0.00 (0 %)
$ 3.64
$ 3.61
$ 2.51 x 10
$ 4.82 x 50
-- - --
$ 1.04 - $ 7.25
27,383
na
54.45M
$ 0.10
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-07-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-13-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-12-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-22-2020 03-31-2020 10-Q
23 03-20-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-09-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 03-13-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-14-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

 Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapyNASHVILLE, Tenn., Oct. ...

 cumberland-pharma-adds-potent-antibiotic-vibativ-to-national-group-purchasing-agreement-with-premier

Premier Membership includes 4,350 U.S. HospitalsNASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc....

 cumberland-pharmaceuticals-ibuprofen-injection-receives-mexican-regulatory-approval-to-treat-pain-and-fever-pisa-to-roll-out-product-in-mexico

Injectable Ibuprofen Approved for Treating Pain & FeverNASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceu...

 correction-cumberland-q2-adj-eps-002-up-from-001-yoy-sales-10838m-up-from-9849m-yoy

Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.02 per share. This is a 100 percent increase over earnings of $0.01 ...

 cumberland-pharma-announces-availability-of-vibativ-4-vial-starter-pak-through-new-contract-with-vizient

Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centersNASHVILLE, Tenn...

 cumberland-pharma-presents-latest-results-from-phase-2-fight-dmd-trial-evaluating-ifetroban-oral-therapy-for-dmd-heart-disease-at-ppmd-conference-in-las-vegas

New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce ca...

 cumberland-pharmaceuticals-and-qureight-partner-to-advance-idiopathic-pulmonary-fibrosis-treatment-research

Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial

 cumberland-q1-adj-eps-016-up-from-005-yoy-sales-1171m-up-from-850m-yoy

Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.16 per share. This is a 420 percent increase over losses of $(0.05) ...

 cumberland-pharmaceuticals-announced-results-from-its-phase-2-fight-dmd-clinical-trial-were-selected-for-late-breaking-presentation-at-the-muscular-dystrophy-association-clinical--scientific-conference-in-dallas

Ifetroban demonstrated significant 5.4% improvement in cardiac function

 cumberland-q4-adj-eps-002-up-from-011-yoy-sales-1044m-up-from-935m-yoy

Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.02) per share. This is a 81.82 percent increase over losses of $(0.11...

 cumberland-pharmaceuticals-and-sciclone-pharmaceuticals-announced-the-national-medical-products-administration-approval-of-cumberlands-vibativ-telavancin-injection-in-china

Vibativ is an antibiotic for pneumonia and serious skin infectionsApproval in China paves the way for launch in world's sec...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION